8-K - Revelation Biosciences, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Revelation Biosciences, Inc. held a Special Meeting on March 18, 2026, where stockholders approved the issuance of common stock pursuant to Class J Common Stock Warrants to exceed the Nasdaq Exchange Cap of 20% of outstanding shares. This approval sets the warrants' expiration date to March 18, 2031, enabling potential exercises without further stockholder consent.

Key Takeaways

1Special Meeting held March 18, 2026, with 4,171,735 shares present (quorum >1/3 of 10,492,469 outstanding shares)

2Proposal 1 approved: issuance of shares under Class J Warrants exceeding 20% Exchange Cap (For: 4,033,345; Against: 104,162; Abstain: 34,228; no broker non-votes)

3Proposal 2 approved: discretionary authority to adjourn meeting (For: 4,044,322; Against: 92,422; Abstain: 34,991; no broker non-votes)

4Class J Warrants issued January 26, 2026, with expiration extended to March 18, 2031 post-approval

5Definitive proxy statement filed February 17, 2026

Current Report Details

Event Type

Securities Modification

Shareholder Vote

Exhibits

Disclosure

Mandatory

Variant

8-K

Items Reported

3.03

Material Modification to Rights of Security Holders. Under Nasdaq rules, a listed company may not issue shares at a price below market value in an amount exceed

Securities Modification

5.07

Submission of Matters to a Vote of Security Holders. At the Special Meeting of the Company, a total of 4,171,735 shares of the Company’s common stock, being gre

Shareholder Vote

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) SIGNATURE

Exhibits Only

Exhibits (1)

8-K